HC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM)

HC Wainwright reiterated their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research note released on Friday,Benzinga reports. HC Wainwright currently has a $2.50 price target on the stock.

IceCure Medical Stock Performance

IceCure Medical stock opened at $1.11 on Friday. The stock’s 50 day moving average is $1.32 and its 200 day moving average is $0.99. The company has a market capitalization of $61.61 million, a P/E ratio of -3.83 and a beta of 0.37. IceCure Medical has a twelve month low of $0.48 and a twelve month high of $1.66. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.07 million. On average, equities research analysts predict that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

Institutional Trading of IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC lifted its holdings in IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,453 shares of the company’s stock after acquiring an additional 14,893 shares during the period. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.